The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shigeo ShimoseAtsushi HiraokaAndrea Casadei-GardiniTsubasa TsutsumiDan NakanoHideki IwamotoFujimasa TadaMargherita RiminiMasatoshi TanakaTakuji TorimuraHideya SugaHideko OhamaValentina BurgioTakashi NiizekiEtsuko MoriyamaHiroyuki SuzukiTomotake ShironoYu NodaNaoki KamachiMasahito NakanoRyoko KuromatsuHironori KogaTakumi KawaguchiPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
MAFLD was a beneficial factor for survival in patients with HCC treated with lenvatinib. Moreover, the better OS of the MAFLD group was more pronounced in patients with non-viral HCC. Lenvatinib may be a suitable agent for patients with non-viral HCC and MAFLD.
Keyphrases